NCT04439175 · Interventional trial
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
Overall registry status Active not recruiting
Phase 2
Conditions Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Delaware Valley sites
- ECOG-ACRIN Cancer Research Group · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory